Skip to content
value.today

Proteostasis Therapeutics Inc.

Total raised
$141 M
4 rounds on record
Latest round
$34 M
Dec 2020
First round on record
Aug 2008
Today
Private
No later event on record

Funding rounds

4 counted as startup funding, 1 other private sales on record. Open the number of investors for the round's details.

Funding rounds of Proteostasis Therapeutics Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Dec 2022$8 MIssued in a merger or acquisition$2 to $10 million

Proteostasis Therapeutics Inc.: Private sale, Dec 2022

Investors in this round

17 investors had bought by the notice of Dec 29, 2022: 17 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 15 investors are named for Proteostasis Therapeutics Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$8 M of $30 M offered; $23 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Craig W. Philips · Executive Officer
  • Keith A. Baker · Executive Officer
  • Shawn Iadonato · Executive Officer, Director
  • David Arkowitz · Director
  • Marion R. Foote · Director
  • Raymond Bartoszek · Director
  • Richard Peters · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On a merger: “The initial sale of the subject securities followed the previously announced merger with Yumanity Therapeutics, Inc.. Such securities were issued to institutional investors and were not offered or issued as consideration in such merger.”

Signed by Shawn P. Iadonato, Chief Executive Officer. Source: SEC Form D, newest notice filed Dec 29, 2022. Read the notice at the SEC.

equitySEC
Dec 2020$34 MNo. 4$10 to $50 million

Proteostasis Therapeutics Inc.: Raise no. 4, Dec 2020

Investors in this round

16 investors had bought by the notice of Jan 6, 2021: 16 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 15 investors are named for Proteostasis Therapeutics Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$34 M of $34 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
$1,716,000
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Brigitte Robertson · Executive Officer
  • N. Anthony Coles · Executive Officer, Director
  • Paulash Mohsen · Executive Officer
  • Richard Peters · Executive Officer, Director
  • Cecil B. Pickett · Director
  • David L. Arkowitz · Director
  • Jeffery W. Kelly · Director
  • Kim C. Drapkin · Director
  • Lynne B. Zydowsky · Director
  • Patricia L. Allen · Director
  • Richard A. Heyman · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • Jefferies LLC (CRD 2347) · New York, New YorkSold in CA, CO, CT, MA, MD, NY, OR, PA, TX

Signed by Paulash Mohsen, Chief Business Officer. Source: SEC Form D, newest notice filed Jan 6, 2021. Read the notice at the SEC.

equitySEC
Sep 2015$22 MNo. 3$10 to $50 million

Proteostasis Therapeutics Inc.: Raise no. 3, Sep 2015

Investors in this round

9 investors had bought by the notice of Sep 15, 2015: 9 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 15 investors are named for Proteostasis Therapeutics Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$22 M of $28 M offered; $6 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities, securities to be acquired by exercising them, other: Series B Convertible Redeemable Preferred Stock
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
$720,000
Finders' fees
none
Paid to its own people
$720,000 (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks sales commissions and payments to its own people as estimates
The company
Corporation, incorporated in Delaware

People named in the notice

  • Janet T. Smart · Executive Officer
  • Meenu James Chhabra · Executive Officer, Director
  • Nadia T. Ustariz · Executive Officer
  • Bernard James Davitian · Director
  • Christopher K. Mirabelli · Director
  • Christopher T. Walsh · Director
  • Conor T. Walshe · Director
  • Henry B. Skinner · Director
  • Jeffery W. Kelly · Director
  • M. James Barrett · Director
  • Stephen W. Knight · Director
  • Irena T. Melnikova · Promoter

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • Leerink Partners LLC (CRD 39011) · broker-dealer Irena Melnikova (CRD 6308893) · Boston, MassachusettsSold in all US states

Remarks in the notice

  • On fees: “$720,000 in sales commission has been paid to Leerink Partners LLC in connection with the amount sold. Additional fees may be paid to Leerink Partners LLC in connection with the amount remaining to be sold.”
  • On the amounts: “Figures in items 13 and 14 include one non-US purchasers investing a total of $1,118,941.”
  • On the use of proceeds: “$720,000 in sales commission has been paid to Leerink Partners LLC (Irena Melnikova) in connection with the amount sold. Additional fees may be paid to Leerink Partners LLC in connection with the amount remaining to be sold.”

Signed by Meenu Chhabra, President and chief executive officer. Source: SEC Form D, newest notice filed Sep 15, 2015. Read the notice at the SEC.

equity, optionsSEC
Jul 2014$15 MNo. 2$10 to $50 million

Proteostasis Therapeutics Inc.: Raise no. 2, Jul 2014

Investors in this round

8 investors had bought by the notice of Sep 15, 2015: 8 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 15 investors are named for Proteostasis Therapeutics Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$15 M of $15 M offered
Smallest investment taken
no minimum stated
What was sold
debt, options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks payments to its own people as estimates
The company
Corporation, incorporated in Delaware

People named in the notice

  • Janet James Smart · Executive Officer
  • Meenu James Chhabra · Executive Officer, Director
  • Nadia James Ustariz · Executive Officer
  • Bernard James Davitian · Director
  • Christopher James Mirabelli · Director
  • Christopher James Walsh · Director
  • Conor James Walshe · Director
  • Henry James Skinner · Director
  • Jeffery James Kelly · Director
  • M. James Barrett · Director
  • Stephen James Knight · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the amounts: “Figures in items 13 and 14 include three non-US purchasers investing a total of $9,069,490.”

Signed by Meenu Chhabra, President and chief executive officer. Source: SEC Form D and 2 amendments, newest notice filed Sep 15, 2015. Read the notice at the SEC.

debt, optionsSEC
Aug 2008$71 MNo. 1$50 to $250 million

Proteostasis Therapeutics Inc.: Raise no. 1, Aug 2008

Investors in this round

7 investors had bought by the notice of Jun 2, 2011: 7 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 15 investors are named for Proteostasis Therapeutics Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$71 M of $82 M offered; $11 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • 06
Meant to last
more than a year
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks payments to its own people as estimates
The company
Corporation, incorporated in Delaware

People named in the notice

  • Pauline Jen Ryan · Executive Officer · Treasurer and Secretary of the Issuer
  • Peter H. Reinhart · Executive Officer, Director, Promoter · President and Chief Scientific Officer of the Issuer
  • Alan K. Walts, Ph.D. · Director
  • Christopher K. Mirabelli · Director
  • Christopher T. Walsh · Director
  • Jeffery W. Kelly · Director
  • Lauren K. Silverman, Ph.D. · Director
  • Stephen K. Knight, M.D. · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the amounts: “Series A Preferred Stock”

Signed by Peter H. Reinhart, President and Chief Scientific Officer. Source: SEC Form D, newest notice filed Jun 2, 2011. Read the notice at the SEC.

equitySEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Proteostasis Therapeutics Inc. chose not to state its revenue in its newest notice of a funding round (Dec 2022).

    SEC Form D · Dec 2022

  • The industry group it chose in its notices: Other Health Care.

    SEC Form D · Dec 2022

That is all the official record says: Proteostasis Therapeutics Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.

Products and services#

No products or services on record: its website did not answer.

Investors#

15 named in official filings. Open an investor to see everything it has backed.

Investors in Proteostasis Therapeutics Inc.
InvestorKindAmountRoundRoleSource
Elan Pharma International LTD.Companynot statednot statedHeld Series A and B preferred stock, 10% owner (Form 3, 2016)SEC Form 3
Fmr LLCFund or asset managernot statednot statedHeld Series A and B preferred stock, 10% owner (Form 3, 2016)SEC Form 3
Franklin M. BergerPersonnot statednot statedHeld Series B preferred stock, director (Form 3, 2016)SEC Form 3
HealthCare Partners VIII, LLCFund or asset managernot statednot statedHeld Series A and B preferred stock, 10% owner (Form 3, 2016)SEC Form 3
HealthCare Partners VIII, L.P.Fund or asset managernot statednot statedHeld Series A and B preferred stock, 10% owner (Form 3, 2016)SEC Form 3
HealthCare Ventures VIII, L.P.Venture capitalnot statednot statedHeld Series A and B preferred stock, 10% owner (Form 3, 2016)SEC Form 3
Nea 12 GP, LLCOthernot statednot statedHeld Series A and B preferred stock, 10% owner (Form 3, 2016)SEC Form 3
NEA Partners 12, Limited PartnershipFund or asset managernot statednot statedHeld Series A and B preferred stock, 10% owner (Form 3, 2016)SEC Form 3
New Enterprise Associates 12, Limited PartnershipFund or asset managernot statednot statedHeld Series A and B preferred stock, 10% owner (Form 3, 2016)SEC Form 3
Novartis AGCompanynot statednot statedHeld Series A and B preferred stock, 10% owner (Form 3, 2016)SEC Form 3
Novartis Bioventures LtdVenture capitalnot statednot statedHeld Series A and B preferred stock, 10% owner (Form 3, 2016)SEC Form 3
PERRIGO Co PLCCompanynot statednot statedHeld Series A and B preferred stock, 10% owner (Form 3, 2016)SEC Form 3
Perrigo Corp LTD.Companynot statednot statedHeld Series A and B preferred stock, 10% owner (Form 3, 2016)SEC Form 3
Perrigo Holdings LTD.Companynot statednot statedHeld Series A and B preferred stock, 10% owner (Form 3, 2016)SEC Form 3
Perrigo Science One LTD.Companynot statednot statedHeld Series A and B preferred stock, 10% owner (Form 3, 2016)SEC Form 3

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 4 rounds above had up to 16 investors.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Proteostasis Therapeutics Inc.
NameRoleNamed in
Craig W. PhilipsExecutive officerDec 2022
Keith A. BakerExecutive officerDec 2022
Shawn IadonatoExecutive officerDec 2022
Brigitte RobertsonExecutive officerJan 2021
N. Anthony ColesExecutive officerJan 2021
Paulash MohsenExecutive officerJan 2021
Richard PetersExecutive officerJan 2021
Janet James SmartExecutive officerSep 2015
Janet T. SmartExecutive officerSep 2015
Meenu James ChhabraExecutive officerSep 2015
Nadia James UstarizExecutive officerSep 2015
Nadia T. UstarizExecutive officerSep 2015
Janet SmartExecutive officerOct 2014
Markus HaeberleinExecutive officerOct 2014
Meenu ChhabraExecutive officerOct 2014
Michael CaseyExecutive officerOct 2014
Walter NewmanExecutive officerOct 2014
Jeffrey GoldbergExecutive officerAug 2014
Pauline Jen RyanTreasurer and Secretary of the IssuerJun 2011
Peter H. ReinhartPresident and Chief Scientific Officer of the IssuerJun 2011
David ArkowitzDirectorDec 2022
Marion R. FooteDirectorDec 2022
Raymond BartoszekDirectorDec 2022
Richard PetersDirectorDec 2022
Shawn IadonatoDirectorDec 2022
Cecil B. PickettDirectorJan 2021
David L. ArkowitzDirectorJan 2021
Jeffery W. KellyDirectorJan 2021
Kim C. DrapkinDirectorJan 2021
Lynne B. ZydowskyDirectorJan 2021
N. Anthony ColesDirectorJan 2021
Patricia L. AllenDirectorJan 2021
Richard A. HeymanDirectorJan 2021
Bernard James DavitianDirectorSep 2015
Christopher James MirabelliDirectorSep 2015
Christopher James WalshDirectorSep 2015
Christopher K. MirabelliDirectorSep 2015
Christopher T. WalshDirectorSep 2015
Conor James WalsheDirectorSep 2015
Conor T. WalsheDirectorSep 2015

About

Company in Boston, United States.